SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-3
Document Type: EX-1.2
Date Filed: 2025-11-26
Accession Number: 0001213900-25-115554
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025115554/ea026681201ex1-2_synergy.htm

Chunk 9 of 18
Word Count: 1399
Character Count: 8834

Document Content:

Prospectus. The Company will furnish to the Agents and their counsel (at the expense of the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein) and all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during the Prospectus Delivery Period (including all documents filed with the Commission during such period that are deemed to be incorporated by reference therein), in each case as soon as reasonably practicable and in such quantities as the Agents may from time to time reasonably request and, at the Agents’ request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may be made; provided, however, that the Company shall not be required to furnish any document (other than the Prospectus) to the Agents to the extent such document is available on EDGAR.

(g) Earnings
Statement. The Company will make generally available to its security holders as soon as practicable, but in any event not later than
15 months after the end of the Company’s current fiscal quarter, an earnings statement covering a 12-month period that satisfies
the provisions of Section 11(a) and Rule 158 of the Securities Act; provided, however, that so long as the Company is subject to
the reporting requirements of either Section 13 or Section 15(d) of the Exchange Act and is timely filing reports with the Commission
on EDGAR, it shall be deemed to be in compliance with the foregoing requirement.

(h) Use
of Proceeds. The Company will use the Net Proceeds as described in the Prospectus in the section entitled “Use of Proceeds.”

(i) Notice
of Other Sales. Without the prior written consent of the Lead Agent, the Company will not, directly or indirectly, offer to sell,
sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant
to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire, Common
Stock during the period beginning on the date on which any Placement Notice is delivered to the Lead Agent hereunder and ending on the
second (2nd) Trading Day immediately following the final Settlement Date with respect to Placement Shares sold pursuant to
such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the sale of all Placement Shares covered
by a Placement Notice, the date of such suspension or termination); and will not directly or indirectly in any other “at the market”
transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock
(other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock,
warrants or any rights to purchase or acquire, Common Stock prior to the termination of this Agreement; provided, however, that such restrictions
will not be required in connection with the Company’s issuance or sale of (i) Common Stock, restricted stock units, options to purchase
Common Stock or Common Stock issuable upon the exercise of options, pursuant to any employee or director stock option or benefits plan,
stock ownership plan or dividend reinvestment plan (but not Common Stock subject to a waiver to exceed plan limits in its dividend reinvestment
plan) of the Company whether now in effect or hereafter implemented, (ii) Common Stock issuable upon conversion of securities or the exercise
of warrants, options or other rights in effect or outstanding, and disclosed in filings by the Company available on EDGAR or otherwise
in writing to the Lead Agent, and (iii) Common Stock, or securities convertible into or exercisable for Common Stock, offered and sold
in a negotiated transaction to vendors, customers, strategic partners or potential strategic partners, acquisition candidates or other
investors conducted in a manner so as not to be integrated with the offering of Common Stock hereby.

(j) Change
of Circumstances. The Company will, at any time during the pendency of a Placement Notice advise the Agents promptly after it shall
have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material respect any
opinion, certificate, letter or other document required to be provided to the Agents pursuant to this Agreement.

(k) Due
Diligence Cooperation. The Company will cooperate with any reasonable due diligence review conducted by the Agents or their representatives
in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents
and senior corporate officers, during regular business hours and at the Company’s principal offices, as the Agents may reasonably
request.

(l) Required
Filings Relating to Placement of Placement Shares. The Company agrees that it will disclose in its annual report on Form 10-K and
its quarterly reports on Form 10-Q, and, if required by any subsequent change in Commission policy or request, more frequently by means
of a Current Report on Form 8-K or a further prospectus supplement to be filed with the Commission under the applicable paragraph of Rule
424(b) under the Securities Act, which will set forth, within the relevant period, the amount of Placement Shares sold through the Agents,
the Net Proceeds to the Company and the compensation payable by the Company to the Agents with respect to such Placement Shares. For all
prospectus supplements filed pursuant to this Section 7(l), the Company agrees to deliver such number of copies of each such prospectus
supplement to each exchange or market on which such sales were effected as may be required by the rules or regulations of such exchange
or market.

(m) Representation
Dates; Certificate. On the date of this Agreement and within five (5) Trading Days of each time the Company:

(i) files
the Prospectus relating to the Placement Shares or amends or supplements (other than a prospectus supplement relating solely to an offering
of securities other than the Placement Shares), the Registration Statement or the Prospectus relating to the Placement Shares by means
of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference into the Registration
Statement or the Prospectus relating to the Placement Shares;

(ii) files
an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or a material
amendment to the previously filed Form 10-K);

(iii) files
a quarterly report on Form 10-Q under the Exchange Act; or

(iv) files
a current report on Form 8-K containing amended financial information (other than information “furnished” pursuant to Items
2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification of certain properties
as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) under the Exchange Act (each date of
filing of one or more of the documents referred to in clauses (i) through (iv) shall be a “Representation Date”); the
Company shall furnish the Agents (but in the case of clause (iv) above only if the Agents reasonably determine that the information contained
in such Form 8-K is material) with a certificate, in the form attached hereto as Exhibit 7(m) (the “Representation Date Certificate”);
provided however, if no Placement Notice is pending at such Representation Date, then before the Company delivers a Placement Notice or
the Lead Agent sells any Placement Shares, the Company shall provide the Agents with a Representation Date Certificate. The requirement
to provide a Representation Date Certificate shall be waived for any Representation Date occurring at a time at which no Placement Notice
is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Placement Notice hereunder (which
for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date; provided, however, that
such waiver shall not apply for any Representation Date on which the Company files its Annual Report on Form 10-K. Notwithstanding the
foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date when the Company relied on such
waiver and did not provide the Agents with a Representation Date Certificate, then before the Company delivers the Placement Notice or
the Lead Agent sells any Placement Shares, the Company shall provide the Agents with a Representation Date Certificate, dated the date
of the Placement Notice.